彭布罗利珠单抗
癌症
免疫组织化学
医学
微卫星不稳定性
癌症研究
生物标志物
免疫疗法
肿瘤科
病理
内科学
生物
基因
微卫星
生物化学
等位基因
作者
Libor Staněk,Robert Gürlich,Zdeněk Musil,Lukáš Havlůj,Alexander C. Whitley
出处
期刊:Bratislavské lekárske listy
日期:2022-01-01
卷期号:123 (02): 83-86
被引量:1
摘要
The anti-PD-1 monoclonal antibody pembrolizumab has been shown to be associated with a good response in patients with metastatic gastric cancer. Excellent therapeutic results of pembrolizumab have been shown in patients with tumours showing a high microsatellite instability (MSI) and Epstein-Barr virus (EBV) positivity.This is a retrospective study of 40 bioptic specimens from the patients, who underwent gastrectomy for gastric carcinoma. The goal of the study was to identify biomarkers (EBV, MLH-1, PDL-1 expression) that are potentially relevant for selecting the patients, who may benefit from PD-1 inhibition therapy.Immunohistochemical (IHC) expression of PDL-1 and MSI, cytogenetic FISH amplification of the HER-2/neu gene and polymerase chain reaction of EBV RNA, including charge quantification, were performed in selected patients with metastatic or advanced gastric cancer.EBV-encoded RNA was detected in nine patients. None of them exhibited Her-2 overexpression or CMV infection. PD-L1 was detected in twelve patients. Ten patients were MLH1 positive. All nine cases of EBV infection showed a high expression of PD-L1 and MLH-1 (Tab. 1, Ref. 14).
科研通智能强力驱动
Strongly Powered by AbleSci AI